SHINING A LIGHT ON BAT CELLULAR IMMUNITY FOLLOWING VIRUS INFECTION
揭示病毒感染后蝙蝠细胞免疫
基本信息
- 批准号:10618969
- 负责人:
- 金额:$ 14.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-06 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAccountingAdaptive Immune SystemAnimalsAntibodiesAntigensAntiviral ResponseAustraliaBindingBiological AssayBiologyCD8B1 geneCellsCellular ImmunityCharacteristicsChiropteraClinicalContainmentDangerousnessDevelopmentDiagnosisDiseaseEpitopesEquus caballusEvolutionFamily PteropodidaeFamily suidaeFatality rateFerretsFossilsGenerationsGenus PteropusGoalsHabitatsHendra VirusHenipavirusHumanImmuneImmune responseImmune systemImmunityImmunohistochemistryImmunologyImmunology procedureIn SituInfectionInnate Immune ResponseInterferon alphaInterventionLightMammalsMediatingModelingMonitorMonoclonal AntibodiesNipah VirusOutcomePathogenesisPathogenicityPeptide/MHC ComplexPeptidesPredispositionProtein ChemistryProteomicsRNA VirusesReadinessReagentRespiratory DiseaseSimuliidaeSoutheastern AsiaStainsT-Cell ReceptorT-LymphocyteUniversitiesValidationViralVirusVirus DiseasesVirus ReplicationVirus SheddingWorkZoonosesadaptive immune responsebat-bornecell mediated immune responseconstitutive expressioncytokinefluinfancyinnovationinsightmortalitynervous system disordernovelnovel therapeuticsnovel vaccinespathogenpreventprotein expressionreceptortooltranscriptometranscriptome sequencingtransmission process
项目摘要
Project summary/abstract
Bats are important reservoir hosts for a variety of viruses, several of which are associated with fatality rates as
high as 90% among diagnosed human cases. This includes the highly pathogenic henipaviruses, of which
Hendra virus (HeV) emerged in Australia and Nipah virus (NiV) in South-east Asia via horse and pig
intermediate hosts respectively. The henipaviruses have been shown to be transmitted from Pteropus bats,
with the Australian black flying fox (Pteropus alecto) confirmed as a reservoir for HeV (1, 2). As with other viral
infections in bats, natural or experimental infection of bats with HeV causes no clinical signs of disease despite
shedding of virus. The antiviral immune response of P. alecto is among the most well studied of all bat species,
with novel immune mechanisms already discovered including the constitutive expression of interferon alpha
discovered by our team (3). These characteristics make the P. alecto – HeV model uniquely suited to
answering the questions we propose in this project. Despite the increasing emergence of zoonotic viruses from
bats, studies of bat immunology remain in their infancy and few studies have examined the adaptive immune
responses of any bat species. Understanding the antiviral responses in bats is crucial if we are to predict and
prevent virus spillover from bats to other susceptible species, understand disease pathogenesis in other
mammals and uncover new therapeutics and vaccines to treat these diseases in humans and other animals.
In this study, we will characterise the innate and adaptive immune response of experimentally infected bats to
HeV to obtain detailed insights into how bats control viral infection. The cell mediated immune response of bats
will be dissected using functional assays to determine the subsets of cells activated during an active infection
and explore global gene and protein expression to characterise the innate and adaptive immune response of
infected bats. The use of innovative approaches to identify MHC bound HeV peptides in infected bats, building
on previous bat immunopeptidomics studies, will provide new insights into peptide presentation during
infection. Few studies have comprehensively studied the immune response of bats during infection, and none
have examined the functional activation of the cell mediated immune response. Comparison with infected
ferrets will allow us to directly compare mechanisms responsible for innocuous (bats) compared to fatal
(ferrets) HeV infection. Expected outcomes include understanding the basic biology of antiviral responses in
bats and the development of new tools to monitor bat immunity to HeV and related viruses.
The Australian Centre for Disease Preparedness and Monash University are uniquely suited for performing the
work outlined in this proposal with a strong track record of working together on bat immunology. The team has
access to high containment facilities and expertise to perform animal infections with dangerous pathogens
combined with access to protein chemistry facilities and expertise in generating tetramer reagents.
项目摘要/摘要
蝙蝠是各种病毒的重要储层宿主,其中几种以死亡率率ac亵,为
在被诊断的人类卡斯中高达90%。
Hendra病毒(HEV)在澳大利亚出现,Nipah病毒(NIV)通过马和猪在东南亚出现
中间宿主分别显示了HENIPAVIRES从pteropus蝙蝠传播
澳大利亚黑色飞狐(pteropus alecto)确认为HEV的Areservoir(1,2)。
蝙蝠的感染,蝙蝠的自然或实验感染HEV,尽管
病毒的脱落。
已经发现了新型免疫机制,包括干扰素α的表达
由我们的团队发现(3)。
回答我们在这个项目中提出的问题。
蝙蝠,对蝙蝠免疫学的研究仍在其起步阶段,很少有研究检查适应性免疫
任何蝙蝠物种的反应,理解蝙蝠的反应至关重要的
防止病毒从蝙蝠从蝙蝠到其他引起的物种的溢出,了解其他疾病发病机理
哺乳动物,并发现新的疗法和疫苗,以信任人类和其他动物中的这些疾病。
在这项研究中,我们将表征实验感染蝙蝠对的先天和适应性免疫反应。
HEV获取有关蝙蝠如何控制病毒感染的详细见解。
将使用功能测定法解剖以确定活性感染中激活的细胞子集
并探索全球基因和蛋白质表达,以表征先天和适应性免疫反应
被感染的蝙蝠。
在先前的BAT免疫肽研究中,将为肽表现提供新的见解
感染。
已经检查了细胞介导的免疫反应的功能激活
雪貂将使我们能够直接比较与致命的机制相比,与致命相比
(雪貂)HEV感染。
蝙蝠和开发新工具来监测对HEV和相关病毒的蝙蝠免疫力。
澳大利亚疾病准备中心和莫纳什大学非常适合执行
在该提案中概述的工作有很强的记录,可以在BAT免疫学上合作
访问具有危险病原体的表演感染的高遏制设施和专业知识
结合获得蛋白质化学设施和产生四聚体试剂的经验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHELLE L BAKER其他文献
MICHELLE L BAKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHELLE L BAKER', 18)}}的其他基金
SHINING A LIGHT ON BAT CELLULAR IMMUNITY FOLLOWING VIRUS INFECTION
揭示病毒感染后蝙蝠细胞免疫
- 批准号:
10449406 - 财政年份:2022
- 资助金额:
$ 14.61万 - 项目类别:
THE INTERFERON RESPONSE OF A MODEL CHIROPTERAN BAT; THE BLACK FLYING FOX, PTEROP
翼手目蝙蝠模型的干扰素反应;
- 批准号:
8360211 - 财政年份:2011
- 资助金额:
$ 14.61万 - 项目类别:
THE INTERFERON RESPONSE OF A MODEL CHIROPTERAN BAT; THE BLACK FLYING FOX, PTEROP
翼手目蝙蝠模型的干扰素反应;
- 批准号:
8168271 - 财政年份:2010
- 资助金额:
$ 14.61万 - 项目类别:
THE MAINTENANCE OF FETAL MATERNAL TOLERANCE IN MARSUPIALS
有袋动物胎儿母体耐受性的维持
- 批准号:
7960516 - 财政年份:2009
- 资助金额:
$ 14.61万 - 项目类别:
THE MAINTENANCE OF FETAL MATERNAL TOLERANCE IN MARSUPIALS
有袋动物胎儿母体耐受性的维持
- 批准号:
7610561 - 财政年份:2007
- 资助金额:
$ 14.61万 - 项目类别:
THE MAINTENANCE OF FETAL MATERNAL TOLERANCE IN MARSUPIALS
有袋动物胎儿母体耐受性的维持
- 批准号:
7382029 - 财政年份:2006
- 资助金额:
$ 14.61万 - 项目类别:
THE MAINTENANCE OF FETAL MATERNAL TOLERANCE IN MARSUPIALS
有袋动物胎儿母体耐受性的维持
- 批准号:
7171260 - 财政年份:2005
- 资助金额:
$ 14.61万 - 项目类别:
THE MAINTENANCE OF FETAL MATERNAL TOLERANCE IN MARSUPIALS
有袋动物胎儿母体耐受性的维持
- 批准号:
6981926 - 财政年份:2004
- 资助金额:
$ 14.61万 - 项目类别:
相似国自然基金
上市公司所得税会计信息公开披露的经济后果研究——基于“会计利润与所得税费用调整过程”披露的检验
- 批准号:72372025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
兔死狐悲——会计师事务所同侪CPA死亡的审计经济后果研究
- 批准号:72302197
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332003
- 批准年份:2023
- 资助金额:166 万元
- 项目类别:重点项目
异常获利、捐赠与会计信息操纵:基于新冠疫情的准自然实验研究
- 批准号:72372061
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
签字注册会计师动态配置问题研究:基于临阵换师视角
- 批准号:72362023
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
相似海外基金
Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypes
肺炎克雷伯菌 O2v1 和 O2v2 O 抗原亚型的免疫识别
- 批准号:
10739041 - 财政年份:2023
- 资助金额:
$ 14.61万 - 项目类别:
Early Onset Parkinson’s disease subtypes and pathogenic mechanisms
早发性帕金森病亚型及致病机制
- 批准号:
10719645 - 财政年份:2023
- 资助金额:
$ 14.61万 - 项目类别:
Antenatal Anxiety and Dyadic Immune Risk(ADIR Study)
产前焦虑和二元免疫风险(ADIR 研究)
- 批准号:
10561867 - 财政年份:2023
- 资助金额:
$ 14.61万 - 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
- 批准号:
10446819 - 财政年份:2022
- 资助金额:
$ 14.61万 - 项目类别: